Actively Recruiting

Age: 18Years +
All Genders
ID06396871

Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases

Led by Technische Universität Dresden · Updated on 2024-05-02

180

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting an observational study to explore the differences in blood cells and circulating molecules in adults with metabolic diseases such as diabetes, obesity, and non-alcoholic fatty liver disease compared to healthy adults. The study aims to measure both the quantity and characteristics of platelets, leukocytes, and other circulating factors to better understand these conditions' shared underlying mechanisms. Participants will be assessed across several groups based on liver fibrosis risk, steatosis presence, and glucose metabolism status. Diagnostic tests include a 75g oral glucose tolerance test with multiple timed blood draws, liver ultrasound to detect fat accumulation, FibroScan to measure liver stiffness, and MRI to precisely quantify liver fat. These tests help categorize participants and evaluate differences in blood components. During the study, participants undergo blood sample collections and various diagnostic scans on the same day to assess platelet and white blood cell qualities and quantities. Researchers will analyze markers like neutrophil and monocyte function, various interleukins, and other blood factors. The study monitors these outcomes within one day of testing, aiming to deepen understanding of metabolic disease impacts on blood and liver health.

CONDITIONS

Brief Title

Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age over 18 years old
  • High risk for significant liver fibrosis with FIB-4 score ≥ 1.3 and Fibroscan ≥ 8 kPa
  • Diagnosis of steatosis by ultrasound and CAP > 275 dB/m
  • Prediabetes defined by HbA1c between 5.7% and 6.5%, or fasting glucose 100-125 mg/dl, or glucose at 120 min of OGTT between 140-200 mg/dl
  • Diabetes defined by HbA1c ≥ 6.5%, or fasting glucose > 126 mg/dl, or glucose at 120 min of OGTT > 200 mg/dl
  • Participants not meeting case group criteria may be included in control groups with low liver fibrosis risk or normal glucose tolerance
Not Eligible

You will not qualify if you...

  • Diagnosis of type 1 diabetes mellitus
  • Body mass index (BMI) less than 18.5 kg/m2
  • Blood transfusion or major bleeding in the last six months
  • Anemia with hemoglobin below 9.0 g/dl
  • Chronic alcohol or drug abuse
  • Acute or chronic liver diseases other than non-alcoholic fatty liver disease
  • Systemic infections with CRP above 1 mg/dl
  • Use of medications affecting blood glucose, coagulation, or immune function in the last six months (except antidiabetics in diabetes group)
  • Pregnancy or breastfeeding
  • Severe psychiatric disorders
  • Inability to follow study protocol
  • Any medical condition unsuitable for study inclusion per investigator opinion
  • MRI-specific exclusions including pacemaker, metal implants, claustrophobia, and others preventing MRI completion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - 1 day

Participants undergo several diagnostic tests including an oral glucose tolerance test, liver ultrasound, Fibroscan, and liver MRI to assess liver status and metabolic health.

1 day of testing including multiple blood draws and imaging

Long-term Monitoring

Duration - Up to 4 years

Participants are observed to understand metabolic and liver disease progression without active intervention.

Follow-up visits as scheduled by the study team

Trial Site Locations

Total: 1 location

1

University Study Center for Metabolic Diseases

Dresden, Saxony, Germany, 01307

Actively Recruiting

Loading map...

Research Team

N

Nikolaos Perakakis, MD

I

Ingo Weigmann, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

7

Similar Trials

"Smart Family Doctor" Assisted Comprehensive Management of S...

Post Coronary Artery Bypass Grafting

Actively Recruiting

1 location

A Bilingual Virtually-based Intervention (PEDALL) for the Pr...

Acute Lymphoblastic Leukemia

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here